BioSyent Inc.

BioSyent Inc.

Share · CA0906901081 (XTSX)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of BioSyent Inc.
No Price
Closing Price XTSX 28.04.2026: 14,50 CAD
28.04.2026 20:00
Current Prices from BioSyent Inc.
ExchangeTickerCurrencyLast TradePriceDaily Change
OTC: UTC
UTC
BIOYF
USD
28.04.2026 20:00
10,65 USD
-0,23 USD
-2,11 %
XTSX: TSX-V
TSX-V
RX.V
CAD
28.04.2026 19:46
14,50 CAD
-0,35 CAD
-2,36 %
Share Float & Liquidity
Free Float 61,45 %
Shares Float 7,07 M
Shares Outstanding 11,5 M
Company Profile for BioSyent Inc. Share
BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Company Data

Name BioSyent Inc.
Company BioSyent Inc.
Website https://www.biosyent.com
Primary Exchange XTSX TSX-V
ISIN CA0906901081
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO René C. Goehrum
Market Capitalization 122 Mio
Country Canada
Currency CAD
Employees 0,1 T
Address 2476 Argentia Road, L5N 6M1 Mississauga
IPO Date 1996-05-08
Dividends from 'BioSyent Inc.'
Ex-Date Dividend per Share
27.02.2026 0,06 CAD
27.02.2026 0,04 USD
28.11.2025 0,05 CAD
29.08.2025 0,05 CAD
30.05.2025 0,05 CAD
30.05.2025 0,04 USD
28.02.2025 0,05 CAD
28.02.2025 0,04 USD
29.11.2024 0,05 CAD
29.11.2024 0,03 USD

Ticker Symbols

Name Symbol
Over The Counter BIOYF
TSX-V RX.V
More Shares
Investors who hold BioSyent Inc. also have the following shares in their portfolio:
GRANITESHARES 3X LONG NETFLIX DAILY ETP
GRANITESHARES 3X LONG NETFLIX DAILY ETP ETN
HCO        NVBO12/15
HCO NVBO12/15 Bond